Ogivri 440 mg

OGIVRI 440 MG is a powder for solution used in intravenous therapy. It contains trastuzumab, a biosimilar medication for targeted treatment. This product is manufactured by Biosimilar Collaborations Ireland Limited.

OGIVRI 440 MG is primarily used in the treatment of certain types of cancer, particularly those that involve the HER2 protein. It is often prescribed for breast cancer and gastric cancer. The medication works by targeting and blocking the action of the HER2 protein, which can help slow or stop the growth of cancer cells. Patients should consult their healthcare provider to determine if this medication is suitable for their specific condition.

Common effects of OGIVRI 440 MG may include fatigue, nausea, and fever. Some patients may experience more severe side effects such as infusion reactions, which can include chills, fever, and difficulty breathing. It is important to monitor for any adverse reactions and report them to a healthcare professional immediately.

OGIVRI 440 MG should be handled with care and prepared by a healthcare professional. It is crucial to follow proper storage and administration guidelines to ensure safety. Patients with a history of heart problems or certain allergies should inform their healthcare provider before starting treatment. Always use this medication under the supervision of a qualified healthcare professional.

OGIVRI 440 MG may interact with other medications, including those that affect the immune system or heart function. It is important to inform your healthcare provider about all medications you are taking to avoid potential interactions. Alcohol and certain supplements may also affect the efficacy and safety of this medication.